Clinical Trials
618
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (575 trials with phase data)• Click on a phase to view related trials
An Evaluation of the Safety and Tolerability of Ocular Lubricants
- Conditions
- Dry Eye Disease
- First Posted Date
- 2025-11-20
- Last Posted Date
- 2025-11-20
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 148
- Registration Number
- NCT07238699
- Locations
- 🇺🇸
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States
🇦🇺School of Optometry and Vision, Sydney, New South Wales, Australia
🇦🇺Ophthalmic Trials Australia, Teneriffe, Queensland, Australia
Surgical Procedure Efficiency Evaluation stuDy
- Conditions
- CataractVitreous HemorrhageRetinal DetachmentMacular PuckerMacular Holes
- First Posted Date
- 2025-11-14
- Last Posted Date
- 2025-11-17
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 180
- Registration Number
- NCT07228091
- Locations
- 🇺🇸
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States
🇬🇧Manchester Royal Eye Hospital, Manchester, United Kingdom
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
- Conditions
- AphakiaPresbyopia
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-10-21
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 120
- Registration Number
- NCT07161635
- Locations
- 🇺🇸
Wolstan & Goldberg Eye Associates, Torrance, California, United States
🇺🇸Moyes Eye Center, Kansas City, Missouri, United States
🇺🇸Carolina Eyecare Physicians LLC, Mt. Pleasant, South Carolina, United States
Feasibility Study of an Accommodating IOL Design
- Conditions
- Aphakia
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-11-13
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 85
- Registration Number
- NCT07147192
- Locations
- 🇺🇸
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States
🇨🇷Clinica 20/20, San José, Costa Rica
🇩🇴Instituto Espaillat Cabral, Santo Domingo, Dominican Republic
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
- Conditions
- Ocular HypertensionOpen Angle Glaucoma
- Interventions
- Drug: Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 470
- Registration Number
- NCT07082816
- Locations
- 🇺🇸
Trinity Research Group, Dothan, Alabama, United States
🇺🇸Eye Doctors of Arizona, Phoenix, Arizona, United States
🇺🇸Orange County Ophthalmology Medical Group, Garden Grove, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 124
- Next